FDA Approves Neurotech Company for Testing Brain Chip in Humans

 

Activist Post reports that brain-computer interface, or BCI, represents the latest frontier of artificial intelligence and biology. While this technology is still early in development, a growing number of companies are already looking at its commercial applications.

On July 28, one of those companies, New York startup Synchron, received FDA approval to test its brain device in human patients. Stentrode, Synchron’s implantable device is small enough to be implanted via a blood vessel at the base of the neck. The device is then maneuvered toward a vessel in the brain.

Stentrode works by communicating through a tiny wire with a second implant in the chest. A transmitter then sends signals to an external computer near the patient.

“We have worked together to pave a pathway forward, towards the first commercial approval for a permanently implanted BCI for the treatment of paralysis”, Thomas Oxley, Synchron CEO, said via Activist Post.

The company plans to enroll six patients in its U.S. trial later this year. According to Oxley, the U.S. study will take a closer look at safety issues, including physical risks and cybersecurity. Activist Post reports an FDA-approved product could be on the market in as soon as 3 to 5 years.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

Doable
Rethinking Leadership: Why “Doable” Might Be the Most Powerful Strategy in Education Today
April 3, 2026

At a time when educator burnout is rising and schools across the U.S. are facing ongoing teacher shortages, leaders are being forced to rethink what sustainable success actually looks like. Research shows that teacher attrition is closely tied to working conditions, job-related stress, and workload demands. As districts push for innovation, data-driven instruction, and…

Read More
Casey Brown
From Poverty to Pricing Power | Why Great Companies Undercharge
April 2, 2026

Casey Brown didn’t grow up thinking she would become an entrepreneur. She grew up in a blue-collar family where money was always tight — close enough to the edge that the fear of poverty shaped many of her early decisions. That fear led her into engineering, into corporate America, and eventually into a moment…

Read More
Nightingales Summit: Empowering the Next Generation of Nigerian Nurses
Nightingales Summit: Empowering the Next Generation of Nigerian Nurses
April 2, 2026

In this episode of Care Anywhere, host Lea Sims sits down with Nigerian nurse entrepreneur and advocate Obafemi Arowosegbe to discuss leadership, mentorship, and the future of nursing in Africa. While still a nursing student, Obafemi founded the Nightingale Summit, a growing conference designed to empower nursing students and early-career nurses with leadership skills,…

Read More
Oncology
From Denial to Access: Rethinking Oncology Care Through AI, Clinical Trials, and Patient-Centered Innovation
April 1, 2026

The rapid expansion of precision medicine, biologics, and targeted cancer therapies is transforming oncology—but it’s also overwhelming a system not built to keep pace. In the U.S., cancer drugs now account for some of the highest-cost treatments in healthcare, and with that has come a surge in prior authorization requirements and denials. Studies suggest physicians…

Read More